Parexel links with Medidata’s Shyft to boost its real-world data offering for clients

hospital computer
Parexel links with Medidata’s Shyft Analytics to boost its real-world evidence offering for biopharma and medical device clients. (Pixabay)

Biopharma services provider Parexel is linking up with Medidata’s Shyft Analytics to boost its real-world evidence (RWE) offering for biopharma and medical device clients.

The collaboration enhances Parexel’s data-linking capabilities through optimizing the design and execution of ongoing and retrospective clinical studies, from late-phase research to supporting clinical trials.

Shyft’s platform allows researchers to generate “submission-ready” studies 92% faster (on average) than the industry standard.

WEBINAR

Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

“By leveraging Shyft’s platform, our teams will be able to generate real-time insights spanning strategic consulting to pivotal trial feasibility to late-phase health economics and outcomes research analytics with a much higher level of efficiency,” Michelle Hoiseth, Parexel’s chief data officer, said in a statement. “This, combined with our enhanced data linking capabilities, is a significant step forward in our approach to help sponsors leverage real-world data in a meaningful way now and in the future.”

As part of its efforts to boost its RWE presence, Parexel partnered with Datavant in September to improve the design and operations of clinical studies. That agreement is designed to connect healthcare data from a number of real-world and clinical data sources to aid drug development and commercialization. Datavant targets secure de-identification and linking of healthcare datasets.

Read more on

Suggested Articles

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical…

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.